Topical Corticosteroid Examples and Potency Classification
Topical corticosteroids are classified into 7 potency classes (Class I being ultra-high potency to Class VII being very low potency), with specific examples including clobetasol propionate 0.05% (Class I), betamethasone dipropionate 0.05% (Class II-III), triamcinolone acetonide 0.1% (Class IV-V), and hydrocortisone 1-2.5% (Class VI-VII). 1
Ultra-High Potency (Class I)
- Clobetasol propionate 0.05% (ointment, cream, foam) 2
- Halobetasol propionate 0.05% (ointment) 2
- Betamethasone dipropionate 0.05% (optimized ointment) 2
These agents achieve efficacy rates of 58-92% in treating moderate to severe psoriasis within 2 weeks, but should be limited to short courses (up to 4 weeks) due to atrophy risk. 2
High Potency (Class II)
- Amcinonide 0.1% 2
- Betamethasone dipropionate 0.05% (cream) 2
- Desoximetasone 0.25% (cream, ointment) 2
- Diflorasone diacetate 0.05% 2
- Fluocinonide 0.05% 2
- Halcinonide 0.1% 2, 3
Medium-High Potency (Class III-IV)
- Betamethasone valerate 0.1% 2
- Fluticasone propionate 0.005% 2
- Mometasone furoate 0.1% 2, 4
- Triamcinolone acetonide 0.1% 2, 5
- Hydrocortisone valerate 0.2% 2
Fluticasone propionate 0.05% cream used twice weekly as maintenance therapy reduces atopic dermatitis relapses by 7-fold compared to vehicle (95% CI: 3.0-16.7). 1
Medium Potency (Class V)
- Betamethasone valerate 0.1% (cream) 2
- Fluocinolone acetonide 0.025% 2
- Hydrocortisone butyrate 0.1% 2
- Prednicarbate 0.1% 2, 4
- Triamcinolone acetonide 0.1% (cream) 2
Medium potency steroids can be utilized for longer courses due to a more favorable adverse event profile compared to ultra-high potency agents. 1
Low Potency (Class VI-VII)
- Hydrocortisone acetate 1% 2, 3
- Hydrocortisone 2.5% (ointment) 5
- Desonide 0.05% 2
- Alclometasone dipropionate 0.05% 4
Anatomic Site-Specific Selection
For face, neck, genitals, and intertriginous areas: Use only low potency agents (Class VI-VII) to minimize atrophy risk. 1, 2
For thick plaques on trunk and extremities: Start with Class I-II agents for rapid control, then transition to lower potency for maintenance. 2
For scalp psoriasis: Class I-VII agents can be used for minimum of 4 weeks as initial and maintenance treatment. 2
Application Regimens
- Acute flares: Most studies support twice daily application, though once daily may suffice for potent agents 1
- Maintenance therapy: Once to twice weekly application of medium potency steroids (e.g., fluticasone propionate 0.05%) reduces relapses with low adverse event rates 1
- Duration limits: Ultra-high potency agents limited to 3 weeks; high/medium potency up to 12 weeks; no time limit for low potency 6
Critical Safety Considerations
Common adverse effects include skin atrophy, striae, telangiectasia, and purpura—highest risk occurs on face, intertriginous areas, and chronically treated sites like forearms. 2
Gradual tapering after clinical improvement is recommended to avoid rebound flares, though exact tapering protocols remain poorly established. 2
Newer agents like mometasone furoate, fluticasone propionate, and prednicarbate offer higher anti-inflammatory effects with once-daily dosing and reduced atrophogenicity compared to older molecules. 4